论文部分内容阅读
关于肿瘤形成于肿瘤始发细胞(tumour-initiating cell)(通俗的名称为肿瘤干细胞)的假设,由于该细胞可能作为一种新的恶性白血病或实体肿瘤治疗的更有效细胞靶点,而受到了广泛的关注。而且,肿瘤始发细胞似乎更具耐药能力,这也解释了目前治疗药物在治疗人类恶性肿瘤中的局限性。尽管仍有许多工作需要去鉴定肿瘤始发细胞的生物学特征,目前已有许多研究致力于开发出新的针对这一细胞的治疗策略。这篇综述总结了近年来在肿瘤干细胞研究领域的进展,并着重探讨在抗肿瘤药物研发方面的挑战和机遇。
The hypothesis that tumors form in tumor-initiating cells (colloquially referred to as tumor stem cells) is compromised by their potential as a new more effective cellular target for the treatment of malignant leukemia or solid tumors Widespread concern. Moreover, tumor-initiating cells appear to be more drug resistant, which also explains the current limitations of therapies in the treatment of human malignancies. Although there is still much work to be done to identify the biological characteristics of tumor-initiating cells, many studies have been devoted to developing new therapeutic strategies for this cell. This review summarizes the recent advances in cancer stem cell research and highlights challenges and opportunities in the development of anticancer drugs.